| Literature DB >> 33111960 |
Céline Phan1, Nathalie Beneton, Juliette Delaunay, Ziad Reguiai, Claire Boulard, Anne-Claire Fougerousse, Elisa Cinotti, Marco Romanelli, Laure Mery-Bossard, Domitille Thomas-Beaulieu, Josiane Parier, François Maccari, Jean-Luc Perrot, Mireille Ruer-Mulard, Marie Bastien, Edouard Begon, Mahtab Samimi, Caroline Jacobzone, Nathalie Quiles-Tsimaratos, Vincent Descamps, Maud Steff, Paul Bilan, Annie Vermersch-Langlin, Mathilde Kemula, Emmanuelle Amazan, Ingrid Kupfer-Bessaguet, Anne-Caroline Cottencin, Francesca Prignano, Bulai Livideanu, Jeremy Gottlieb, Alain Beauchet, Emmanuel Mahé.
Abstract
Anti-interleukin-17 agents have recently been developed for the treatment of psoriasis. This study evaluated the tolerance and effectiveness of anti-interleukin-17 agents for psoriasis in elderly patients in daily practice. A multicentre, retrospective study was performed, involving psoriatic patients aged ≥65 years who had received an anti-interleukin-17 agent, including secukinumab, ixekizumab or brodalumab. A total of 114 patients were included: 72 received secukinumab, 35 ixekizumab, and 7 brodalumab. Treatment was stopped in 32 patients (28.9%), because of relapses in 14 patients (41.2%), primary failures in 11 patients (32.4%), or adverse events in 7 patients (20.6%). The 3 most frequently reported adverse events were injection site reactions (n = 4), oral candidiasis (n = 3), and influenza-like illness (n = 3). Regarding effectiveness, 80 patients (70%) reached a Physician Global Assessment score of 0/1, 6 months after treatment initiation. In conclusion, anti-interleukin-17 therapy appears to be an effective and safe therapeutic option for psoriasis treatment in patients aged ≥ 65 years.Entities:
Keywords: anti-interleukin 17; drug survival; elderly; safety; psoriasis
Mesh：
Substances：
Year: 2020 PMID： 33111960 PMCID： PMC9309849 DOI： 10.2340/00015555-3678
Source DB: PubMed Journal: Acta Derm Venereol ISSN： 0001-5555 Impact factor: 3.875